

CUMULATIVE INDEX 1995

Volume 13

January	GENODERMATOSES WITH MALIGNANT POTENTIAL, pages 1-243
April	COSMETIC DERMATOLOGY, pages 245-503
July	DERMATOEPIDEMIOLOGY, pages 505-716
October	PSORIASIS, pages 717-955

Note: Page numbers of article titles are in **boldface** type.

Acitretin. See *Systemic retinoids*.
Acne, active, dermabrasion for, 315
Acne scarring, dermabrasion for, 313-315
Acquired melanocytic nevi, **595-603**
analytic studies of, in adults, 596-599
in children, 599, 601
clinical definition and enumeration of, 596
Acrodermatitis continua, management of, 775
Actinic keratosis, interferons for, **703-704**
Acyclovir, for herpes simplex infection, in HIV infection, 232-233
for varicella-zoster virus, in HIV infection, 233
Adenocarcinoma, gastrointestinal, in Peutz-Jeghers syndrome, 130
of colon, in Gardner's syndrome, 54
Adenoma sebaceum, in tuberous sclerosis complex, 152
Adenomas, pituitary, in Carney complex, 24
Adenomatous colon polyps, in Gardner's syndrome, 54, 55
African iron overload, malignancies associated with, 59-60
Aging face, etiology of, 245
photoaging in, 245-247
cellular and molecular aspects of, 246-247
classification of, 247
clinical aspects of, 245-246
histology of, 247
treatment of, **245-261**
alpha-hydroxy acids in, 248-249
chemical peels in. See *Chemical peels*.
cryopeels in, 253
dermabrasion in. See *Dermabrasion*.
moisturizers in, 248
soft tissue augmentation in. See *Microlipoinjection*.
sunscreens in, 248
topical tretinoin in, 249, 251
AIDS, Kaposi's sarcoma in. See *Kaposi's sarcoma*.
Alcohol, role of, in psoriasis, 639-641, 718, 796
Alexandrite lasers, in cosmetic dermatology, 455
Allergens, role of, in atopic dermatitis, 655
Allergic reactions, blepharoplasty and, 421
Alpha-hydroxy acids, for aging face, 248-249
Amenorrhea, systemic glucocorticosteroids and, 934-935
Amyloidosis, lichen, in multiple endocrine neoplasia 2/A, 92
Analgesia, in tumescent liposuction, 337
Anesthesia, for chemical peels, 269
for dermabrasion, 320
for lower lid blepharoplasty, 409
for tumescent liposuction, 329-330
for upper lid blepharoplasty, 400, 402
Angioedema, drug-induced, 685-686
Angiofibromas, facial, in tuberous sclerosis complex, 152
Angiomyolipomas, renal, in tuberous sclerosis complex, 154, 156
Angiotensin-converting enzyme inhibitors, and angioedema, 686
Ankylosing spondylitis, vs. psoriatic arthritis, 788
Anthralin, for psoriasis, 822-829
clinical uses of, 824-829
modification of Ingram regimen, 824-825
short-contact regimens, 825-827
with phototherapy, 827-829, 869
formulations and pharmacology of, 822-823
mechanism of action of, 823
side effects of, 823-824
Antibiotics, for Lyme disease, 539-540
for psoriasis, **909-913**
choice of drug in, 911-913
historical aspects of, 909-910
laboratory results in, 910-911
pretherapy evaluation for, 910
prophylactic, in tumescent liposuction, 337
Antibody-containing blood products, receipt of, as contraindication to measles vaccination, 557-558
Antigen-presenting cells, in psoriasis, 739-740
Antimalarials, for porphyrias, 141
Aphthous stomatitis, in HIV infection, 237
Argon lasers, in cosmetic dermatology, 449
Argon-pumped tunable dye lasers, in cosmetic dermatology, 450
Arthritis, psoriatic. See *Psoriatic arthritis*.
with psoriasis, 725
Arytenoid ethyl ester. See *Systemic retinoids*.
Ash leaf spots, in tuberous sclerosis complex, 151-152
Astrocytomas, giant cell, in tuberous sclerosis complex, 156, 160
Ataxia-telangiectasia, **1-6**
malignancies associated with, 2

Ataxia-telangiectasia (*Continued*)
 mucocutaneous stigmata of, 1–2
 noncutaneous features of, 2
 work-up for, 2–5

Atherosclerosis, systemic glucocorticosteroids and, 934

Atopic dermatitis, 649–657
 definition of, 649–653
 applying hospital criteria in population setting, 650–651
 categoric or dimensional, 650
 diagnostic criteria for, 651
 statistical, prognostic, operational, or clinical, 649–650
 UK working party refinement of, 651–653

descriptive epidemiology of, 653–656
 environmental factors in, 654–655
 fetal and infant influences in, 654
 genetics in, 654
 natural history in, 654
 prevalence and morbidity in, 653–654
 in Wiskott-Aldrich syndrome, 68

interferons for, 702
 prevention of, 655–656

Autologous collagen, microlipoinjection of. See *Microlipoinjection*.

Autologous fat, microlipoinjection of. See *Microlipoinjection*.

Axillary freckling, in neurofibromatosis, 106–107

Azidothymidine, with interferons, for AIDS-related Kaposi's sarcoma, 701

Bacillary angiomatosis, in HIV infection, 231–232

Bacille Calmette-Guérin vaccination, against leprosy, 533

Bacterial infections, in chemical peels, 310
 in HIV infection. See *HIV infection*.
 in Wiskott-Aldrich syndrome, 68

Baker-Gordon solution, for chemical peels, 269–270

Basal cell carcinoma, in nevoid basal cell carcinoma syndrome, 114
 increased risk of, therapy for psoriasis and, 860

interferons for, 702–703

Bazex syndrome, basal cell carcinoma in, 120–121

Beckwith-Wiedemann syndrome, 211–214
 malignancies associated with, 214
 mucocutaneous stigmata of, 212–214
 noncutaneous features of, 214

Behcet's disease, interferons for, 706

Benign pigmented nevi, and melanoma, screening for, 629

Benoxaprofen, for psoriasis, 917

Betamethasone dipropionate, for psoriasis, 810

Biologic response modifiers, for psoriasis, 745

Biopsies, liver, to monitor methotrexate therapy, for psoriasis, 880

Birt-Hogg-Dube syndrome, malignancies associated with, 214–216

Blepharoplasty, 389–430
 indications for, 389
 long-term results of, 427, 430
 lower lid measurements for, 400
 lower lid skin and muscle technique for, 417–418
 lower lid skin flap technique for, 409, 416–417
 patient consultation for, 389
 patient evaluation for, 389–390
 patient examination for, 390–395
 laboratory tests in, 395
 ophthalmic, 394–395

photographs in, 395–399
 preoperative, 390, 392–394

postoperative care for, 418

postoperative follow-up examination for, 418–427

preoperative instructions and release for, 399

preoperative marking for, 399–400

preoperative preparation for, 399

transconjunctival lower lid procedure in, 409

upper lid measurements for, 400

upper lid operative procedure in, 400, 402–409

Blindness, blepharoplasty and, 423, 427

Bloch-Sulzberger syndrome, malignancies associated with, 219–220

Blood cell effects, of systemic glucocorticosteroids, 935

Blood transfusions, and leishmaniasis, 516–517

Bloom's syndrome, 7–18
 clinical features of, 8–11
 explanation for, 13–14
 diagnosis of, 16
 etiology of, 14–16
 genetics in, 14–15
 genomic instability in, 15–16
 malignancies associated with, 12–13
 management of, 16–18
 non-sun-sensitive lesions in, 12
 sun-sensitive facial lesions in, 11–12

Blue nevi, in Carney complex, 20

Bone marrow transplantation, for dyskeratosis congenita, 37
 for Fanconi anemia, 46

Borrelia burgdorferi. See *Lyme disease*.

Bowenoid papulosis, human papillomavirus in, 568, 569

interferons for, 706

Bowing, lateral, blepharoplasty and, 422

Breast lesions, in Cowden syndrome, 28

Burns, role of, in skin cancer, 591

Café-au-lait macules, in neurofibromatosis, 105–106

Calcipotriol, for psoriasis, 743, 835–841, 916
 in HIV infection, 236
 indications for, 838
 mechanism of action of, 835–837
 safety of, 837–838
 side effects of, 837
 with phototherapy, 836–837, 848, 918
 for pustular psoriasis, 763

Camouflage therapy, in cosmetic dermatology, 467–472
 application of, 464
 color blending in, 471
 color correction in, 471
 duplication of skin imperfections in, 471–472
 indications for, 467–468
 limitations of, 471
 materials for, 468, 471
 patient evaluation for, 468
 patient goals in, 468
 principles of, 464
 resources for, 472
 techniques for, 471
 vs. makeup artists, 467

Cancer, of colon, in Birt-Hogg-Dube syndrome, 216
 of skin. See *Skin cancer*.
 of thyroid, in Gardner's syndrome, 54

Candidiasis, in HIV infection, 234–235

Cannulas, sizes of, for tumescent liposuction, 330

Capsaicin, for psoriasis, 917

Carbon dioxide lasers, in cosmetic dermatology, 448–449

Carcinoma, basal cell, in nevoid basal cell carcinoma syndrome, 114
 increased risk of, therapy for psoriasis and, 860
 interferons for, 702–703

colorectal, in Muir-Torre syndrome, 86

hepatocellular, in HLA-linked hemochromatosis, 59
 in porphyrias. See *Porphyrias*.

medullary thyroid, in Birt-Hogg-Dube syndrome, 215–216
 in multiple endocrine neoplasia 2A, 94
 in multiple endocrine neoplasia 2B/3, 101–102

periampullary, in Gardner's syndrome, 54

squamous cell, increased risk of, therapy for psoriasis and, 859–860
 interferons for, 703–704

Cardiac fibromas, in nevoid basal cell carcinoma syndrome, 119

Cardiac myxomas, in Carney complex, 22

Cardiovascular abnormalities, in tuberous sclerosis complex, 154

Cardiovascular disease, increased risk of, therapy for psoriasis and, 720

Cardiovascular effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Carney complex, 19–26
 mucocutaneous stigmata of, 20–21
 noncutaneous features of, 22–24
 cardiac myxomas, 22
 myxoid mammary fibroadenomas, 23–24
 pituitary adenomas, 24
 primary pigmented nodular adrenal disease, 22–23
 psammomatous melanotic schwannomas, 24
 testicular large cell calcifying Sertoli cell tumors, 24

Cataracts, juvenile posterior subcapsular, in neurofibromatosis, 108
 systemic glucocorticosteroids and, 932

Caustic solutions, in sclerotherapy, for varicose and telangiectatic veins, 441–442

Cellular effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Cellular radiation sensitivity, in nevoid basal cell carcinoma syndrome, 120

Central nervous system, malignancies of, in Gardner's syndrome, 54

Cervical dysplasia, human papillomavirus in, 567–568

Chédiak-Higashi syndrome, malignancies associated with, 67–68

Cheeks, microlipoinjection of autologous fat in, 344

Chemical peels, for aging face, 255, 257
 complications of, 309–312
 procedural side effects, 309–310
 glycolic acid in, 285–307
 acid application in, 291, 293
 complications of, 294–295
 histology of, 295
 indications for, 286–289
 mechanism of action of, 285
 medications and combination therapies in, 290
 postoperative care for, 293–295
 prepeel planning in, 289–290
 results of, 295, 297
 skin preparation for, 290–293
 immediately prepeel, 291
 two to four weeks prior to peel, 290–291
 with other peeling agents, 295

Jessner's-trichloroacetic acid in, medium-depth peels, 277–283
 complications of, 282–283
 method for, 277–282
 patient consultation for, 277–278

postoperative care for, 281–282
 preoperative preparation for, 278–279
 results of, 282–283

trichloroacetic acid and phenol in, 263–276
 classification of agents for, 263
 deep peels, 265–271
 complications of, 271
 informed consent for, 269
 intraoperative monitoring and anesthesia for, 269
 mixing and application of solution for, 269–270
 patient postoperative visits after, 270–271
 pretreatment of skin for, 269
 relative contraindications to, 268–269
 taping and postoperative care for, 270
 histology of, 274
 historical aspects of, 263
 medium-depth peels, 271–274
 patient selection for, 263–265
 superficial peels, 274
 vs. dermabrasion, 258

Chemicals, exposure to, and skin cancer, 590

Chemosis, blepharoplasty and, 419

Chemosurgery, as contraindication to dermabrasion, 317
 vs. dermabrasion, 325–326

Chemotherapy, for psoriasis, 5-fluorouracil, 885–887, 915
 hydroxyurea, 875, 885–886
 mechanism of action of, 876
 mechlorethamine, 887
 methotrexate. See *Methotrexate*.
 6-thioguanine, 875, 886
 thiotapec, 887
 topical methotrexate, 887

Chondrosarcoma, in Maffucci's syndrome, 74

Chromated glycerin, in sclerotherapy, for varicose and telangiectatic veins, 442

Chromosome instability, in nevoid basal cell carcinoma syndrome, 120

Chronic granulomatous disease, interferons for, 702

Cigarette smoking, role of, in psoriasis, 641, 718

Cirrhosis, methotrexate and, for psoriasis, 881, 919

Cleft lip and palate, in nevoid basal cell carcinoma syndrome, 118

Clobetasol propionate, for psoriasis, 810

Clotrimazole, for candidiasis, in HIV infection, 234

Cockayne's syndrome, vs. xeroderma pigmentosum, 194–195

Collagen, autologous, microlipoinjection of. See *Microlipoinjection*.

Colon, adenocarcinoma of, in Gardner's syndrome, 54
 cancer of, in Birt-Hogg-Dube syndrome, 216
 polyposis of, in Birt-Hogg-Dube syndrome, 215

Colorectal carcinoma, in Muir-Torre syndrome, 86

Complete blood count, to monitor methotrexate therapy, for psoriasis, 879

Compression, after sclerotherapy, for varicose and telangiectatic veins, 442

Condyloma acuminatum, in HIV infection, 233–234
 interferons for, 699–701

Contact dermatitis, anthralin and, for psoriasis, 824
 occupational. See *Occupational contact dermatitis*.
 topical corticosteroids and, for psoriasis, 812

Contact sensitization, in sunscreen intolerance, 473–475, 477–478

Contact urticaria, in sunscreen intolerance, 478

Contour defects, blepharoplasty and, 421–422

Copper bromide lasers, in cosmetic dermatology, 451, 456

Corneal irritation, blepharoplasty and, 419
 Corticosteroids, systemic. See *Systemic corticosteroids*.
 topical. See *Topical corticosteroids*.
 Cosmetic dermatology, blepharoplasty in. See
Blepharoplasty.
 camouflage therapy in. See *Camouflage therapy*.
 chemical peels in. See *Chemical peels*.
 cosmetics in. See *Cosmetics*.
 dermabrasion in. See *Dermabrasion*.
 for aging face. See *Aging face*.
 hair transplantation in. See *Hair transplantation*.
 lasers in. See *Lasers*.
 microinjection of autologous collagen in. See
Microinjection.
 microlipoinjection of autologous fat in. See
Microinjection.
 sclerotherapy in. See *Sclerotherapy*.
 sunscreen intolerance in. See *Sunscreen intolerance*.
 tumescent liposuction in. See *Tumescent liposuction*.
 Cosmetics, in postsurgical patient, 461–465
 camouflage therapy in. See *Camouflage therapy*.
 eye cosmetics in, 463
 facial foundations in, 462
 lip cosmetics in, 463
 powders and blushers in, 463
 removal of, 463–464
 skin care and, 461–462
 incisional wounds, 461
 large surface area wounds, 461–462
 undercover foundations in, 463
 Cowden syndrome, 27–31
 breast lesions in, 28
 diagnosis of, 27
 eye lesions in, 29
 gastrointestinal lesions in, 29
 genitourinary tract abnormalities in, 29
 management of, 30–31
 mucocutaneous stigmata of, 27–28
 pathophysiology of, 30
 skeletal abnormalities in, 29
 thyroid gland lesions in, 28
 Cross-sensitization reactions, in sunscreen intolerance, 475–476
 Cryopeels, for aging face, 257
 Cushing's syndrome, in Carney complex, 22–23
 topical corticosteroids and, for psoriasis, 811
 Cutaneous effects, of systemic glucocorticosteroids. See
Systemic glucocorticosteroids.
 Cutaneous malignant melanoma, 605–612
 genetic epidemiology of, 605–609
 candidate gene p16 in, 607
 chromosome 1p in, 606
 chromosome 9p in, 606–607
 complexities of, 607–609
 description, 605
 future studies in, 609
 principles of linkage analysis, 605–606
 public health issues in, 609–610
 education, 610
 screening and management, 609–610
 Cyclosporine, for erythrodermic psoriasis, 769
 for psoriasis, 743–744, 897–907, 917, 920
 dosage and schedule for, 899–900
 follow-up of, 905
 indications for, 903–905
 mechanism of action of, 897, 899
 pharmacokinetics of, 899
 pretherapy evaluation for, 904–905
 side effects of, 900–903
 with methotrexate, 884, 903–904
 with phototherapy, 871, 904
 for psoriatic arthritis, 791
 Cysts, epidermoid, in Gardner's syndrome, 51–52
 mesenteric, in nevoid basal cell carcinoma syndrome, 119
 renal, in tuberous sclerosis complex, 156

Dardour flaps, in hair transplantation, 383
 Dental abnormalities, in Gardner's syndrome, 53
 Depigmentation, chemical peels and, 271
 Dermabrasion, 313–327
 adjunctive procedures with, 323–325
 anesthesia for, 320
 complications of, 322–323
 contraindications to, 317–318
 for acne scarring, 313–315
 for active acne, 315
 for aging face, 257–261
 vs. chemical peels, 258
 for rhytides, 315–316
 for tattoo removal, 316
 for vitiligo, 316
 indications for, 313
 instrumentation for, 319–320
 office and staffing considerations in, 320
 patient education and informed consent for, 318
 patient selection for, 313
 physician qualifications and technical skills for, 318
 postoperative care for, 321–322
 preoperative planning for, 318–319
 repeat, 326
 techniques for, 321
 vs. chemosurgery or laser surgery, 325–326
 Dermatitis, atopic. See *Atopic dermatitis*.
 occupational contact. See *Occupational contact dermatitis*.
 seborrheic, in HIV infection, 235–236
 Dermatoepidemiology, dermatologic health services
 research in, 689–695
 avoidance of bias in, 693–694
 data measurement in, 693
 data sources in, 693
 generalizability in, 694
 patient sample in, 693
 patient's perspective on, 692
 physician's perspective on, 690–692
 developing and measuring outcome, 690–692
 profiling types of care, 690
 research question in, 693
 society's perspective on, 692
 study design in, 693
 of acquired melanocytic nevi. See *Acquired melanocytic nevi*.
 of atopic dermatitis. See *Atopic dermatitis*.
 of cutaneous malignant melanoma. See *Cutaneous malignant melanoma*.
 of drug reactions. See *Drug reactions*.
 of epidermolysis bullosa. See *Epidermolysis bullosa*.
 of human papillomaviruses. See *Human papillomaviruses*.
 of Kaposi's sarcoma. See *Kaposi's sarcoma*.
 of leishmaniasis. See *Leishmaniasis*.
 of leprosy. See *Leprosy*.
 of Lyme disease. See *Lyme disease*.
 of measles. See *Measles*.
 of melanoma. See *Melanoma*.
 of occupational contact dermatitis. See *Occupational contact dermatitis*.

Dermatoepidemiology (*Continued*)
 of psoriasis. See *Psoriasis*.
 of skin cancer. See *Skin cancer*.
 terminology in, 697-698

Dermatophytosis, in HIV infection, 235

Desmoid tumors, in Gardner's syndrome, 52

Detergent solutions, in sclerotherapy, for varicose and telangiectatic veins, 440-441

Diabetes mellitus, in Bloom's syndrome, 9

Diepoxybutane test, for Fanconi anemia, 42

Diet, role of, in psoriasis, 641-642, 718-719
 in skin cancer, 590-591

Dihydrofolate reductase inhibitors, for psoriasis, with methotrexate, 885

DNA repair, for Rothmund-Thomson syndrome, 148

Doppler ultrasound, in physical examination of varicose and telangiectatic veins, 435-437

Drug reactions, cutaneous, 681-688
 angioedema, 685-686
 rates of, 682-683
 serum sickness and serum sickness-like reactions, 685
 sources of information on, 681-682
 toxic epidermal necrolysis, 683-684

Dry eye syndrome, blepharoplasty and, 422

Duncan's disease, malignancies associated with, 69-70

Duplex ultrasound, in physical examination of varicose and telangiectatic veins, 439

Dyskeratosis congenita, 33-39
 clinical evaluation of, 37
 cutaneous stigmata in, 33-34
 malignancies associated with, 35-37
 management of, 37-38
 noncutaneous features of, 34-37
 hematologic, 35
 physical, 34-35
 vs. Fanconi anemia, 37

Dysplastic nevi, and melanoma, screening for, 629

Dystrophic nails, in dyskeratosis congenita, 34

Ear abnormalities, in Beckwith-Wiedemann syndrome, 213

Eccymosis, blepharoplasty and, 419

Ectropion, blepharoplasty and, 419, 422

Edema, blepharoplasty and, 421
 systemic glucocorticosteroids and, 934

Electrodessication, with dermabrasion, 325

Elliot flaps, in hair transplantation, 382

Enchondromas, in Maffucci's syndrome. See *Maffucci's syndrome*.

Endocrine overactivity, in Carney complex. See *Carney complex*.

Endothelial cells, in psoriasis, 732, 741-742

Enthesopathy, in psoriatic arthritis, 782-783, 785, 789-790

Entropion, blepharoplasty and, 422

Epidermal atrophy, topical corticosteroids and, for psoriasis, 812

Epidermolytic hyperplasia verruciformis, human papillomavirus in, 564

Epidermoid cysts, in Gardner's syndrome, 51-52

Epidermolysis bullosa, 659-670
 and skin cancer, 666-667
 disease registries of, 663-664
 National Epidermolysis Bullosa Registry, 664-667
 examples of data from, 665-667
 epidemiology of, 659-663
 classification and subclassification in, 661

clinical outcomes in, 662
 differential surveillance in, 660
 misclassification bias in, 660-661
 natural history in, 662
 observational or informational bias in, 661
 phenotypes and genotypes in, 662-663
 prevalence and incidence in, 662
 quality of laboratory tests in, 661-662
 selection bias in, 659-660
 socioeconomic impact in, 662

Erythema, anthralin and, for psoriasis, 823-824
 blepharoplasty and, 419, 421
 chemical peels and, 311
 dermabrasion and, 322

Erythrodermic psoriasis, 763-769
 clinical features of, 764
 histopathology of, 764, 768
 provocative factors in, 768
 treatment of, 768-769
 systemic retinoids in, 892-893
 with psoriasis vulgaris, 763

Ethanolamine oleate, in sclerotherapy, for varicose and telangiectatic veins, 441

Ethyl chloride, in anesthesia, for dermabrasion, 320

Etreteinate, for psoriasis. See *Systemic retinoids*.

Excited skin syndrome, in patch testing, for sunscreen intolerance, 478

Extender of Frechet, in hair transplantation, 384-385

Eyelids, chemical peels of, Jessner's-trichloroacetic acid in, 281

Face lift, as contraindication to chemical peels, for aging face, 269

Facial angiomas, in tuberous sclerosis complex, 152

Facial hemiatrophy, microlipoinjection of autologous fat for, 345

Familial atypical multiple mole melanoma syndrome, malignancies associated with, 216-218

Familial melanoma. See *Cutaneous malignant melanoma*.

Fanconi anemia, 41-49
 bone marrow transplantation for, 46
 diepoxybutane test for, 42
 international registry of, patient features in, 42-46
 congenital malformations, 43-45
 hematologic abnormalities, 45-46
 molecular studies of, 46-47
 umbilical cord blood transplantation for, 46
 vs. dyskeratosis congenita, 37

Fat, autologous, microlipoinjection of. See *Microlipoinjection*.

Female sex hormones, role of, in skin cancer, 590

Fetal effects, of systemic glucocorticosteroids, 935

Fetal rhabdomyomas, in nevoid basal cell carcinoma syndrome, 120

Fibrel. See *Microlipoinjection, of autologous collagen*.

Fibroadenomas, myxoid mammary, in Carney complex, 23-24

Fibroblasts, in psoriasis, 731-732

Fibrofolliculomas, in Birt-Hogg-Dube syndrome, 215

Fibromas, cardiac, in nevoid basal cell carcinoma syndrome, 119

ovarian, in nevoid basal cell carcinoma syndrome, 119-120

perifollicular, in Birt-Hogg-Dube syndrome, 215

ungual, in tuberous sclerosis complex, 152

Fibroplasia, impaired, systemic glucocorticosteroids and, 935

Fibrotic diseases, interferons for, 707-708

FK506, for psoriasis, 744, 917
 for psoriatic arthritis, 791

Flaps, in hair transplantation. See *Hair transplantation*.

Flashlamp-pumped pulsed dye lasers, in cosmetic dermatology, 450–451, 456

5-Fluorouracil, for psoriasis, 886–887, 915
 with methotrexate, 885

Follicular mucinosis, interferons for, 706

Foscarnet, for herpes simplex infection, in HIV infection, 232

Freckling, axillary, in neurofibromatosis, 106–107

Freons, in anesthesia, for dermabrasion, 320

Frequency-doubled Nd:YAG lasers, in cosmetic dermatology, 456

Fumaric acid esters, for psoriasis, 920

Fungal infections, in HIV infection, 234–235

Gardner's syndrome, 51–56
 cutaneous stigmata in, 51–52
 evaluation, management, and follow-up of, 54–55
 malignancies associated with, 54
 noncutaneous features of, 52–54

Gastrointestinal effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Gastrointestinal ganglioneuromatosis, in multiple endocrine neoplasia 2B/3, 100

Gastrointestinal lesions, in Cowden syndrome, 29

Gastrointestinal malignancies, in Peutz-Jeghers syndrome, 129–131

Genital herpes simplex infection, interferons for, 705

Genital human papillomavirus. See *Human papillomaviruses*.

Genitourinary tract abnormalities, in Cowden syndrome, 29

Genodermatoses, ataxia-telangiectasia. See *Ataxiatelangiectasia*.

Beckwith-Wiedemann syndrome. See *Beckwith-Wiedemann syndrome*.

Birt-Hogg-Dube syndrome, 215–216

Bloom's syndrome. See *Bloom's syndrome*.

Carney complex. See *Carney complex*.

Cowden syndrome. See *Cowden syndrome*.

dyskeratosis congenita. See *Dyskeratosis congenita*.

familial atypical multiple mole melanoma syndrome, 216–218

Fanconi anemia. See *Fanconi anemia*.

Gardner's syndrome. See *Gardner's syndrome*.

hereditary tylosis, 218–219

HLA-linked hemochromatosis. See *HLA-linked hemochromatosis*.

immunodeficiency syndromes. See *Immunodeficiency syndromes*.

incontinentia pigmenti, 219–220

Maffucci's syndrome. See *Maffucci's syndrome*.

Muir-Torre syndrome. See *Muir-Torre syndrome*.

multiple endocrine neoplasia 2/2A. See *Multiple endocrine neoplasia 2/2A*.

multiple endocrine neoplasia 2B/3. See *Multiple endocrine neoplasia 2B/3*.

neurofibromatosis. See *Neurofibromatosis*.

nevroid basal cell carcinoma syndrome. See *Nevoid basal cell carcinoma syndrome*.

Peutz-Jeghers syndrome. See *Peutz-Jeghers syndrome*.

porphyrias. See *Porphyrias*.

Rothmund-Thomson syndrome. See *Rothmund-Thomson syndrome*.

supernumerary nipples, 220–226

tuberous sclerosis. See *Tuberous sclerosis complex*.

Werner's syndrome. See *Werner's syndrome*.

xeroderma pigmentosum. See *Xeroderma pigmentosum*.

Genomic instability, in Bloom's syndrome, 15–16

Giant cell astrocytomas, in tuberous sclerosis complex, 156, 160

Glabellar furrows, microlipoinjection of autologous fat for, 343–344

Glaucoma, systemic glucocorticosteroids and, 932–933

Giomas, optic nerve, in neurofibromatosis, 108–109

Glucocorticosteroids, systemic. See *Systemic glucocorticosteroids*.

Glycolic acid, in chemical peels. See *Chemical peels*.

Goeckerman regimen, for psoriasis, 820–822

Grafts, in hair transplantation. See *Hair transplantation*.

island. See *Island grafts*.

Griseofulvin, for dermatophytosis, in HIV infection, 235

Growth factor therapy, for dyskeratosis congenita, 37

Growth retardation, systemic glucocorticosteroids and, 931–932

Guttate psoriasis, clinical features of, 751–752
 histopathology of, 753

HLA markers in, 752–753
 response to therapy in, 753, 755

Gynecologic effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Hair transplantation, 363–387
 grafting in, 365–377
 avoiding compression on, 371
 combination micrografting with strip harvesting in, 368, 370
 grading of, 374
 placing grafts in, 376–377
 planning for session size in, 371–372
 pre- and postoperative instructions in, 370–371
 producing recipient site for, 376
 removing epidermis in, 374–375
 standard micrografting session in, 366
 strip harvesting technique in, 372–375
 hair-bearing flaps in, 380–385
 Dardour flap, 383
 Elliot flap, 382
 extender of Frechet, 384–385
 instrumentation advances in, 385
 Juri flap, 381–382
 Nataf flap, 382–383
 newer flaps worldwide, 383–384
 historical aspects of, 363
 ideal candidates for, 363–365
 recipient site for, 365
 scalp reduction in, 377–380
 bilateral lateral technique for, 380
 stretch back and long-term benefits of, 378–379

Hamartomas, retinal, in tuberous sclerosis complex, 152, 154

Hamartomatous polyps, in Peutz-Jeghers syndrome, 128

Hands, microlipoinjection of autologous fat in, 345
 papillomas of, 563

Hemangioma, interferons for, 706

Hematologic abnormalities, in dyskeratosis congenita, 35
 in Fanconi anemia, 45–46

Hematologic effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Hematomas, blepharoplasty and, 422–423

Hemihypertrophy, in Beckwith-Wiedemann syndrome, 214

Hemochromatosis, HLA-linked. See *HLA-linked hemochromatosis*.

Heparol, in sclerotherapy, for varicose and telangiectatic veins, 441

Hepatitis infections, as contraindication to dermabrasion, 317-318

Hepatocellular carcinoma, in HLA-linked hemochromatosis, 59
in porphyrias. See *Porphyrias*.

Hereditary tylosis, malignancies associated with, 218-219

Herpes simplex hepatitis, methotrexate and, for psoriasis, 882

Herpes simplex infections, as contraindication to chemical peels, for aging face, 268
as contraindication to dermabrasion, 317
genital, interferons for, 705
in chemical peels, 310
in HIV infection, 232-233

Herpes zoster, interferons for, 705-706
methotrexate and, for psoriasis, 882

HIV infection, as contraindication to dermabrasion, 317-318
as contraindication to measles vaccination, 557
skin diseases in, 231-238
 bacterial infections, 231-232
 bacillary angiomatosis, 231-232
 Staphylococcus aureus infections, 231
 syphilis, 232

 papulosquamous diseases, 235-237
 aphthous stomatitis, 237
 generalized pruritus, 237
 papular dermatoses, 236-237
 psoriasis and Reiter's disease, 236, 719, 726
 seborrheic dermatitis, 235-236

 viral infections, 232-235
 herpes simplex, 232-233
 human papillomavirus, 233-234
 molluscum contagiosum, 233
 mucocutaneous fungal infections, 234-235
 oral hairy leukoplakia, 233
 varicella-zoster virus, 233

with leprosy, 533

with porphyrias, 139-140

with psoriatic arthritis, 781, 789, 791

HLA-linked hemochromatosis, 57-63
diagnosis and treatment of, 60-62
historical aspects of, 57-58
incidence of, 57
malignancies associated with, 59-60
mucocutaneous stigmata of, 58-59
noncutaneous features of, 59
pathogenesis of, 58

Hormones, female sex, role of, in skin cancer, 590

Human immunodeficiency virus infection. See *HIV infection*.

Human papillomaviruses, 561-574
 biologic characteristics of, affecting epidemiology, 562
 detection of, 561-562
 genital, 566-570
 frequency of, 566-567
 in children, 568-570
 natural history and relation to malignancy of, 567-568
 in epidermodysplasia verruciformis, 564
 in HIV infection, 233-234
 in immunocompetent patients, 564, 566
 in immunosuppressed patients, 564
 nongenital cutaneous, 562-564

Hydroxyurea, for psoriasis, 875, 885-886
for pustular psoriasis, 762

Hyperglycemia, systemic glucocorticosteroids and, 933-934

Hyperlipidemia, systemic glucocorticosteroids and, 934

Hyperpigmentation, chemical peels and, 271, 294-295, 309
 dermabrasion and, 323

Hypertension, cyclosporine and, for psoriasis, 902
 systemic glucocorticosteroids and, 934

Hypertonic dextrose and saline, in sclerotherapy, for varicose and telangiectatic veins, 441

Hypertonic saline, in sclerotherapy, for varicose and telangiectatic veins, 441

Hypertrophic scarring, chemical peels and, 294, 311
 dermabrasion and, 323

Hypoglycemia, in Beckwith-Wiedemann syndrome, 214

Hypogonadism, in nevoid basal cell carcinoma syndrome, 118

Hypomelanotic macules, in tuberous sclerosis complex, 151-152

Hypopigmentation, chemical peels and, 271, 295, 309
 dermabrasion and, 323

Hypothalamic-pituitary-adrenal axis, and systemic glucocorticosteroids, 927, 936-937

Immune system, compromised, as contraindication to measles vaccination, 557

Immunocompetent patients, human papillomavirus in, 564, 566

Immunocompromised patients, human papillomavirus in, 564
 skin cancer in, 590

Immunodeficiency, in ataxia-telangiectasia, 3 in Bloom's syndrome, 9-10

Immunodeficiency syndromes, 65-71
 Chédiak-Higashi syndrome, 67-68
 panhypoglobulinemia syndromes, 65-67
 Wiskott-Aldrich syndrome, 68-69
 X-linked lymphoproliferative disorder, 69-70

Immunologic effects, of PUVA therapy, for psoriasis, 858-859

Immunomodulatory agents, for psoriasis, 920

Immunosuppression, systemic glucocorticosteroids and, 935

Immunotherapy, for psoriasis. See *Psoriasis*.

Incontinentia pigmenti, malignancies associated with, 219-220

Infections, bacterial, in Wiskott-Aldrich syndrome, 68
 chemical peels and, 271, 294, 310
 in HIV infection. See *HIV infection*.
 methotrexate and, for psoriasis, 882
 role of, in psoriasis, 641, 718, 725-726, 741

Infertility, methotrexate and, for psoriasis, 882

Ingram regimen, for psoriasis, 824-825

Insulin-like growth factor 2, in Beckwith-Wiedemann syndrome, 212

Interferons, dermatologic uses of, 699-711
 FDA-approved, 699-702
 AIDS-related Kaposi's sarcoma, 701
 chronic granulomatous disease, 702
 condyloma acuminatum, 699-701
 for human papillomavirus infection, in HIV infection, 234
 non-FDA-approved, 702-708
 actinic keratosis and squamous cell carcinoma, 703-704
 atopic dermatitis, 702
 basal cell carcinoma, 702-703
 Behcet's disease, 706
 follicular mucinosis, 706
 genital herpes simplex, 705

Interferons (Continued)

- hemangioma, 706
- herpes zoster, 705–706
- keratoacanthoma, 705
- lupus erythematosus, 706
- melanoma, 704–705
- mycosis fungoides, 705
- psoriatic arthritis, 706–707
- systemic sclerosis and fibrotic diseases, 707–708
- verruca vulgaris/bowenoid papulosis, 706

Intraocular pressure, increase in, blepharoplasty and, 423

Ionizing radiation, role of, in skin cancer, 590

Iron overload. See *HLA-linked hemochromatosis*.

Irritant solutions, in sclerotherapy, for varicose and telangiectatic veins, 441–442

Island grafts, to close wound defects, 483–498

- elliptical primary defect, 490, 492
- irregular primary defect, 483–484, 487
- named? geometric primary defect, 487, 490, 492
- trapezoidal primary defect, 490
- triangular primary defect, 487
- unusual primary defect, 492, 498

Isotretinoin, for psoriasis, with PUVA therapy, 871

- prior use of, as contraindication to dermabrasion, 317

Itraconazole, for candidiasis, in HIV infection, 235

Jessner's–trichloroacetic acid, in chemical peels. See *Chemical peels*.

Jordan light, in Goeckerman therapy, for psoriasis, 821

Juri flaps, in hair transplantation, 381–382

Juvenile posterior subcapsular cataracts, in neurofibromatosis, 108

Kaposi's sarcoma, 575–582

- AIDS-related, 575, 577–581

- epidemiologic variables in, 578–580

- clustering by person, place, and time, 579–580

- person, 578–579

- place, 579

- time, 579

- etiology of, 580–581

- interferons for, 701

- historical aspects of, 575

Karyotyping, of ataxia-telangiectasia, 3

Keloids, interferons for, 707–708

Keratinocytes, in psoriasis, 731, 740

Keratoacanthomas, in Muir-Torre syndrome, 81–82

- interferons for, 705

Keratoconjunctivitis sicca, blepharoplasty and, 422

Keratocysts, odontogenic, in nevoid basal cell carcinoma syndrome, 115–116

Ketoconazole, for candidiasis, in HIV infection, 235

- for dermatophytosis, in HIV infection, 235

Kidney abnormalities, in nevoid basal cell carcinoma syndrome, 118

Kidney disease, cyclosporine and, for psoriasis, 902–903

Koebner reaction, in psoriasis, 726–727

Krypton lasers, in cosmetic dermatology, 451, 456

Lagophthalmus, blepharoplasty and, 422

Laser surgery, vs. dermabrasion, 325–326

Lasers, in cosmetic dermatology, 447–460

- alexandrite lasers, 455

argon lasers, 449

argon-pumped tunable dye lasers, 450

carbon dioxide lasers, 448–449

copper bromide lasers, 451

for pigmented lesions, 455–456

frequency-doubled Nd:YAG lasers, 456

krypton lasers, 451

Nd:YAG lasers, 454–455

physics of, 447

Q-switched lasers, 451, 453–455

ruby lasers, 453–454

tissue interaction with, 447–448

visible light lasers, 449–451

yellow light lasers, 449–451

Leishmaniases, 505–523

- clinical features of, 507–508

- cutaneous, 507–508

- visceral, 508

- diagnosis of, 508–509

- epidemiologic triangle in, 511–513

- anthroposes, 512

- New World, 512

- Old World, 512

- reservoir hosts, 511

- sand fly vector, 513

- geographic distribution of, 510–511

- incidence and prevalence of, 509–510

- life cycle of, 505–506

- modes of transmission in, 516–517

- prevention and control of, 518

- risk factors for, 513, 515–516

- taxonomy of, 5–6

- treatment of, 509

- tropism in, 506–507

Lentigines, in Carney complex, 20

Leprosy, 525–536

- classification of, 526

- clinical features of, 525–528

- detection rates in, 532–533

- epidemiology of, 528–532

- future trends in, 533–535

- nerve damage in, 527–528

- treatment of, 532

- vaccination against, 533

Leucovorin, with methotrexate, for psoriasis, 885

Leucovorin rescue, for methotrexate overdose, in psoriasis, 883

Leukopenia, methotrexate and, for psoriasis, 881

Leukoplakia, in dyskeratosis congenita, 34

Lichen amyloidosis, in multiple endocrine neoplasia 2/2A, 92

Lipids, elevation of, systemic retinoids and, for psoriasis, 894

Liposuction, tumescent. See *Tumescent liposuction*.

Lips, microlipoinjection of autologous fat in, 344

- upper, dermabrasion of, 259–261

Lisch nodules, in neurofibromatosis, 108

Liver biopsies, to monitor methotrexate therapy, for psoriasis, 880

Liver disease, methotrexate and, for psoriasis, 881–882

- systemic retinoids and, for psoriasis, 894

Liver function tests, to monitor methotrexate therapy, for psoriasis, 879–880

Lung disease, methotrexate and, for psoriatic arthritis,

- 790–791

Lupus erythematosus, interferons for, 706

Lupus profundus, microlipoinjection of autologous fat for, 344–345

Lyme disease, 537–551

- diagnosis of, 539

Lyme disease (*Continued*)
 epidemiology of, 540–546
 alternate vectors, 542
 disease emergence, 545–546
 distribution of disease and its tick vectors, 540, 542
 risk factors, 546
 surveillance statistics, 543–545
 transmission of spirochete, 540
 vertebrate hosts, 542–543
 etiology of, 537–538
 host-parasite interaction in, 538–539
 prevention of, 546–547
 treatment of, 539–540
 Lymphoreticular malignancies, in Wiskott-Aldrich syndrome, 69

Macroglossia, in Beckwith-Wiedemann syndrome, 212–213

Maffucci's syndrome, 73–78
 malignancies associated with, 74
 mucocutaneous stigmata of, 73
 noncutaneous features of, 73–74
 work-up and follow-up of, 74–77

Measles, 553–559
 clinical features of, 553–554
 diagnosis of, 554
 epidemiology of, 554–555
 prevention of, 555–556
 vaccination against, 556–557
 adverse reactions to, 557
 contraindications to, 557–558
 improvements in, 558

Mechlorethamine, for psoriasis, 887

Medullary thyroid carcinoma, in Birt-Hogg-Dube syndrome, 215–216
 in multiple endocrine neoplasia 2A, 94
 in multiple endocrine neoplasia 2B/3, 101–102

Medulloblastoma, in nevoid basal cell carcinoma syndrome, 118–119

Melanoma, cutaneous malignant. See *Cutaneous malignant melanoma*.
 in xeroderma pigmentosum, 188–189
 increased risk of, therapy for psoriasis and, 720
 interferons for, 704–705
 screening for, 623–634
 definitions and applications of, 624–625
 education and early detection programs in, 625–626
 international, 631–632
 in high-risk people, 629–630
 mass screening, 626–628
 educational effects of, 627–628
 risk profiles in, 627
 visual examination in, 626–627
 yield of, 626
 outcome measures in, 625
 professional education in, 630–631
 self-screening, 628–629

Melolabial furrows, microlipoinjection of autologous fat for, 344

Mesenteric cysts, in nevoid basal cell carcinoma syndrome, 119

Metabolic effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Methotrexate, for erythrodermic psoriasis, 768
 for psoriasis, 743, 817–818, 875–890, 919
 contraindications to, 878
 current uses of, 877–878
 dosage and schedule for, 879

historical aspects and efficacy of, 876–877
 in HIV infection, 236
 indications for, 877
 mechanism of action of, 876
 monitoring of, 879–880
 patient selection for, 878
 pharmacology of, 877
 pretherapy evaluation for, 878
 side effects of, 880–883
 antidote to, 883
 drug interactions, 882–883
 hematologic, 881
 hepatic, 881–882
 infectious, 882
 infertility, 882
 topical, 887, 915
 with cyclosporine, 884, 903–904
 with dihydrofolate reductase inhibitors, 885
 with 5-fluorouracil, 885
 with leucovorin, 885
 with phototherapy, 848, 869–870, 883–884
 with systemic retinoids, 884
 for psoriatic arthritis, 790
 for pustular psoriasis, 762

8-Methoxysoralen. See *PUVA therapy*.

Microlipoinjection, of autologous collagen, for dermal defects, 347–350
 complications of, 349
 Fibrel in, 251, 353–361
 adverse reactions to, 359
 contraindications to, 356
 Fibrel kit in, 355–356
 future uses of, 359–360
 historical aspects of, 353–354
 indications for, 356
 injection techniques for, 356–358
 mechanism of action of, 354–355
 results of, 358–359
 skin test procedure in, 356
 historical aspects of, 347–348
 longevity of, 349–350
 technique for, 348–349

of autologous fat, for aging face, 251, 255
 for dermal defects, 339–347
 complications of, 345
 historical aspects of, 339
 indications for, 343–345
 longevity of, 345, 347
 microlipoextraction of fat in, 339–340
 reimplantation of fat in, 342–343
 treatment of collected fat in, 340

Milia, blepharoplasty and, 421
 chemical peels and, 310
 dermabrasion and, 323
 in nevoid basal cell carcinoma syndrome, 114

Moisturizers, for aging face, 248

Molecular studies, of Fanconi anemia, 46–47

Molluscum contagiosum, in HIV infection, 233

Mometasone furoate, for psoriasis, 916

Morphea, microlipoinjection of autologous fat for, 344–345

Mucosal neuromas, in multiple endocrine neoplasia 2B/3, 99

Muir-Torre syndrome, 79–89
 cutaneous stigmata in, 81–82
 historical aspects of, 79–81
 incidence of, 79
 malignancies associated with, 86
 noncutaneous features of, 82, 86
 work-up and follow-up of, 87

Multiple endocrine neoplasia 2/2A, 91–97
 mucocutaneous stigmata of, 92
 noncutaneous features of, 92–95

Multiple endocrine neoplasia 2B/3, 99–103
 diagnosis and screening of, 102–103
 malignancies associated with, 101–102
 mucocutaneous stigmata of, 99–100
 noncutaneous features of, 100–101

Multiple hamartoma syndrome. See *Cowden syndrome*.

Musculoskeletal abnormalities, in multiple endocrine neoplasia 2B/3, 100–101

Musculoskeletal effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
 of systemic retinoids, for psoriasis, 894

Mycophenolic acid, for psoriasis, 875–876

Mycosis fungoides, interferons for, 705

Myopathy, systemic glucocorticosteroids and, 932

Myxomas, in Carney complex. See *Carney complex*.

Nail disease, with psoriatic arthritis, 785–786

Nails, dystrophic, in dyskeratosis congenita, 34
 psoriasis of, 772–773

Nasolabial furrows, microlipoinjection of autologous fat for, 344

Natraf flaps, in hair transplantation, 382–383

Nd:YAG lasers, in cosmetic dermatology, 454–455

Neoplastic effects, of PUVA therapy, for psoriasis, 859–860

Nervous system effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Neurofibromas, in neurofibromatosis, 107–108

Neurofibromatosis, 105–111
 malignancies associated with, 108–110
 optic nerve gliomas, 108–109
 peripheral nerve sheath tumors, 109
 pheochromocytoma, 110
 spinal tumors, 109
 vestibular schwannomas, 109
 mucocutaneous stigmata of, 105–108
 axillary freckling, 106–107
 café-au-lait macules, 105–106
 neurofibromas, 107–108
 noncutaneous features of, 108
 work-up and follow-up of, 110–111

Neurologic abnormalities, in tuberous sclerosis complex, 156
 in xeroderma pigmentosum, 189–190

Neuromas, mucosal, in multiple endocrine neoplasia 2B/3, 99

Neurons, in psoriasis, 742

Neuropsychiatric effects, of systemic glucocorticosteroids, 936

Nevi, acquired melanocytic. See *Acquired melanocytic nevi*.
 benign pigmented, and melanoma, screening for, 629
 dysplastic, and melanoma, screening for, 629

Nevoid basal cell carcinoma syndrome, 113–125
 basal cell carcinoma in, 114
 cardiac fibroma in, 119
 chromosome instability and cellular radiation sensitivity in, 120
 fetal rhabdomyoma in, 120
 general appearance of, 113–114
 heredity in, 120
 medulloblastoma in, 118–119
 mesenteric cysts in, 119
 milia in, 114

musculoskeletal radiographic findings in, 116–118
 odontogenic keratocysts in, 115–116
 ovarian fibromas in, 119–120
 palmar and plantar pits in, 115

Nevus flammeus, facial, in Beckwith-Wiedemann syndrome, 213–214

Nitrogen mustard, for psoriasis, 887

Nonmelanoma skin cancer, PUVA therapy and, for psoriasis, 859–860

Nonsolar ultraviolet radiation, role of, in skin cancer, 589–590

Nonsteroidal anti-inflammatory drugs, for psoriatic arthritis, 789–790

Obesity, systemic glucocorticosteroids and, 934

Obstetric effects, of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.

Occupational contact dermatitis, 671–680
 epidemiology of, 671–673
 problems in assessing, 672–673
 etiology of, 677
 population at risk for, 675–677
 prevention of, 677–678
 prognosis for, 677
 public health issues in, 673–675
 United States Bureau of Labor Statistics data on, 673
 workers' compensation data on, 674–675

Ocular abnormalities, in Cowden syndrome, 29
 in dyskeratosis congenita, 34
 in Gardner's syndrome, 53–54
 in multiple endocrine neoplasia 2B/3, 99–100
 in nevoid basal cell carcinoma syndrome, 118
 in Rothmund-Thomson syndrome, 146
 in tuberous sclerosis complex, 152, 154

Ocular apraxia, in ataxia-telangiectasia, 2

Odontogenic keratocysts, in nevoid basal cell carcinoma syndrome, 115–116

Ophthalmologic effects, of PUVA therapy, for psoriasis, 858
 of systemic glucocorticosteroids. See *Systemic glucocorticosteroids*.
 of systemic retinoids, for psoriasis, 895

Optic nerve gliomas, in neurofibromatosis, 108–109

Oral abnormalities, in dyskeratosis congenita, 34
 in Rothmund-Thomson syndrome, 145

Oral cavity, papillomas of, 564

Oral commissures, microlipoinjection of autologous fat for, 344

Oral hairy leukoplakia, in HIV infection, 233

Osmotic solutions, in sclerotherapy, for varicose and telangiectatic veins, 441

Osteomas, in Gardner's syndrome, 52–53, 54–55

Osteonecrosis, systemic glucocorticosteroids and, 930–931

Osteoporosis, systemic glucocorticosteroids and, 929–930

Osteosarcoma, in Rothmund-Thomson syndrome, 147

Ovarian fibromas, in nevoid basal cell carcinoma syndrome, 119–120

Ovarian tumors, in Peutz-Jeghers syndrome, 130

Palmar and plantar pits, in nevoid basal cell carcinoma syndrome, 115

Palmoplantar psoriasis, 773–775
 differential diagnosis of, 773
 diseases associated with, 774

Palmoplantar psoriasis (*Continued*)
 etiology of, 773
 histopathology of, 774
 treatment of, 774-775
 with psoriasis, 774

Pancytopenia, methotrexate and, for psoriasis, 881

Panhypoglobulinemia syndromes, malignancies associated with, 65-67

Poplar dermatoses, in HIV infection, 236-237

Populosoquamous diseases, in HIV infection. See *HIV infection*.

Patch testing, for sunscreen intolerance, 471-472

Pentavalent antimonials, for leishmaniasis, 509

Peptic ulcer disease, systemic glucocorticosteroids and, 933

Periampullary carcinoma, in Gardner's syndrome, 54

Perifollicular fibromas, in Birt-Hogg-Dube syndrome, 215

Peripheral nerve sheath tumors, in neurofibromatosis, 109

Perthes' test, modified, in physical examination, of varicose and telangiectatic veins, 434-435

Peutz-Jeghers syndrome, 127-133
 clinical course of, 128-129
 malignancies associated with, 129-130
 mucocutaneous stigma of, 127-128
 noncutaneous features of, 128
 work-up and follow-up of, 130-131

Phenol, in chemical peels. See *Chemical peels*.

Pheochromocytoma, in multiple endocrine neoplasia 2B/3, 102
 in neurofibromatosis, 110

Phlebotomy therapy, for HLA-linked hemochromatosis, 62
 for porphyrias, 141

Photoaging. See *Aging face*.

Photocontact sensitization, in sunscreen intolerance, 473-475, 477-478

Photodermatoses, sunscreen intolerance in, 476-477

Photoplethysmography, in physical examination, of varicose and telangiectatic veins, 437, 439

Phototesting, for Rothmund-Thomson syndrome, 147-148
 for sunscreen intolerance, 477-478

Phototherapy. See also *PUVA therapy; UVB therapy*.
 for erythrodermic psoriasis, 769
 for papular dermatoses, in HIV infection, 236-237
 for psoriasis, 841-849, 917-919
 electromagnetic spectrum of, 842
 erythemogenic vs. suberythemogenic, 844
 for maintenance therapy, 845
 frequency of, 844
 home administration of, 847
 in HIV infection, 236
 indications for, 845
 photobiologic effects of, 842
 PUVA plus UVB therapy, 848
 side effects of, 845-847
 tars vs. emollients in, 843-844
 treatment schedules for, 843
 ultraviolet irradiators in, 842-843
 vs. tars, 821-822
 with anthralin, 827-829, 869
 with calcipotriol, 836-837, 848, 918
 with cyclosporine, 871, 904
 with methotrexate, 848, 869-870, 883-884
 with systemic retinoids, 848, 870-871, 893-894, 918
 with topical corticosteroids, 810, 847-848, 868-869
 for pustular psoriasis, 762-763

Pigmentation, dark, as contraindication to dermabrasion, 318

disturbances of, chemical peels and, 271, 294-295, 309, 311
 dermabrasion and, 323

spotty, in Carney complex. See *Carney complex*.

Pigmented lesions, removal of, lasers in, 455-456

Pituitary adenomas, in Carney complex, 24

Plaque psoriasis, clinical features of, 751-752
 histopathology of, 753
 HLA markers in, 752-753
 response to therapy in, 753, 755
 systemic retinoids for, 893

Podophyllin, for human papillomavirus infection, in HIV infection, 233-234

Polidocanol, in sclerotherapy, for varicose and telangiectatic veins, 440

Polyiodide iodine, in sclerotherapy, for varicose and telangiectatic veins, 441-442

Polypsis, of colon, in Birt-Hogg-Dube syndrome, 215

Polyps, adenomatous colon, in Gardner's syndrome, 54, 55
 hamartomatous, in Peutz-Jeghers syndrome, 128

Porphyrias, 135-142
 cutaneous stigma of, 137-138
 differential diagnosis of, 140
 evaluation of, 140
 liver involvement in, 138-139
 noncutaneous features of, 139
 treatment of, 140-141

Post-kala azar leishmaniasis, clinical features of, 507-508

Pregnancy, as contraindication to measles vaccination, 557

Proptosis, blepharoplasty and, 419

Propylthiouracil, for psoriasis, 917

Pruritus, in HIV infection, 237
 PUVA therapy and, for psoriasis, 858

Psammomatous melanotic schwannomas, in Carney complex, 24

Pseudotumor cerebri, systemic glucocorticosteroids and, 936

Psoriasis, 635-647
 clinical course of, predicting and modifying, 642-644
 diseases associated with, 719-721
 epidemiology of, 717-722
 age effect in, 636-637
 disease occurrence in, 636
 genetic, 637-639, 717-718
 nongenetic host and environmental factors in, 639-642
 alcohol, 639-641, 718, 796
 diet, 641-642, 718-719
 drugs, 641, 719
 infections, 641, 718, 725-726, 741
 smoking, 641, 718
 stress, 641
 trauma, 641

erythrodermic. See *Erythrodermic psoriasis*.

guttate. See *Guttate psoriasis*.

immunopathogenesis of, 739-742
 antigen-presenting cells in, 739-740
 endothelial cells in, 741-742
 keratinocytes in, 740
 neurons in, 742
 T-lymphocytes in, 740-741
 in HIV infection, 236
 in problem sites, 771-777
 acrodermatitis continua, 775
 nails, 772-773
 palmoplantar. See *Palmoplantar psoriasis*.
 scalp, 771-772

Psoriasis (Continued)

- natural history and prognosis of, 642–643
- pathogenesis of, 723–737
 - compartmental localization of cellular markers in, 729–732
 - genetics in, 723–724
 - in involved and uninvolved skin, 728–729
 - Koebner reaction in, 726–727
 - trigger factors in, 725–726
- plaque. See *Plaque psoriasis*.
- prevalence of, 717
- psychological aspects of, 793–804
 - behavioral techniques, 801
 - depression, 795–796
 - doctor-patient relationship, 799–800
 - group therapy, 800–801
 - impact of disease, 793–795
 - individual psychotherapy, 800
 - patient education, 799
 - stress, 796–799
- pustular. See *Pustular psoriasis*.
- risk factors for, 718–719
- treatment of, 643–644, 727–728
 - and increased risk of cancer, 719–720
 - anthralin in. See *Anthralin*.
 - antibiotics in. See *Antibiotics*.
 - calcipotriol in. See *Calcipotriol*.
 - chemotherapy in. See *Chemotherapy*.
 - cyclosporine in. See *Cyclosporine*.
 - future of, 915–923
 - advances in phototherapy, 917–919
 - new systemic therapies, 919–920
 - new topical therapies, 915–917
 - immunotherapy in, 742–745
 - biologic response modifiers, 745
 - exogenous immunomodulation, 742–744
 - highly specific, 744–745
 - methotrexate in. See *Methotrexate*.
 - phototherapy in. See *Phototherapy*.
 - PUVA therapy in. See *PUVA therapy*.
 - systemic retinoids in. See *Systemic retinoids*.
 - tars in. See *Tars*.
 - topical corticosteroids in. See *Topical corticosteroids*.
 - UVB therapy in. See *UVB therapy*.
- Psoriasis vulgaris, with erythrodermic psoriasis, 763
- with pustular psoriasis, 757
- Psoriatic arthritis**, 719, 725, 779–792
 - clinical features of, 783–786
 - joint disease, 784–786
 - onset, 783–784
 - skin disease, 784
 - course and prognosis of, 787
 - diagnosis of, 787–789
 - differential diagnosis of, 788–789
 - epidemiology of, 643, 779–780
 - etiology and pathogenesis of, 780–782
 - environmental factors in, 781–782
 - gene identification in, 780–781
 - genetic factors in, 780
 - HIV infection in, 781
 - immunogenetic factors in, 781
 - immunologic mechanisms in, 783
 - interferons for, 706–707
 - laboratory findings in, 786
 - pathology of, 782–783
 - pustulosis palmaris and plantaris and SAPHO with, 786
 - radiographic features of, 786–787
 - treatment of, 789–791
- Psychiatric problems**, as contraindication to dermabrasion, 318
- Ptosis**, blepharoplasty and, 422
- Pulmonary abnormalities**, in tuberous sclerosis complex, 156
- Punch elevation**, with dermabrasion, 323
- Punch excision**, and full-thickness graft replacement, with dermabrasion, 323, 325
- Pustular psoriasis**, 757–763
 - clinical features of, 757, 759
 - histopathology of, 759, 761
 - provocative factors in, 761–762
 - treatment of, 762–763
 - systemic retinoids in, 892
 - with psoriasis vulgaris, 757
- Pustulosis palmaris and plantaris**, with psoriatic arthritis, 786
- PUVA therapy**. See also *Phototherapy*.
 - for erythrodermic psoriasis, 769
 - for palmoplantar psoriasis, 774–775
 - for psoriasis, 643–644, 828–829, 851–866, 917–918
 - and increased risk of cancer, 720
 - choice of drug in, 852–853
 - choice of radiation in, 853
 - histologic changes in, 860–863
 - historical aspects of, 851
 - modifications of, 867–873
 - current status of, 871
 - with anthralin, 869
 - with calcipotriol, 869
 - with cyclosporine, 871
 - with methotrexate, 869–870
 - with systemic retinoids, 870–871
 - with topical corticosteroids, 868–869
 - with UVB therapy, 870
 - side effects of, 857–860
 - immunologic, 858–859
 - neoplastic, 859–860
 - ophthalmologic, 858
 - technique for, 853–856
 - topical, 856–857
 - with calcipotriol, 837, 918
 - with methotrexate, 884
 - with systemic retinoids, 918
 - for pustular psoriasis, 763
 - role of, in skin cancer, 590
 - Q-switched lasers**, in cosmetic dermatology, 451, 453–455
 - Radiation**, ionizing, role of, in skin cancer, 590
 - Radiodermatitis**, as contraindication to dermabrasion, 317
 - Radiosensitivity assays**, of ataxia-telangiectasia, 4–5
 - Rapamycin**, for psoriasis, 744
 - Rasmussen syndrome**, basal cell carcinoma in, 121
 - Reiter's disease**, in HIV infection, 236
 - Reiter's syndrome**, vs. psoriatic arthritis, 788–789
 - Renal abnormalities**, in supernumerary nipples, 222
 - in tuberous sclerosis complex, 154, 156
 - Renal transplant patients**, human papillomavirus in, 564
 - Respiratory papillomatosis**, clinical features of, 563–564
 - Retinal damage**, blepharoplasty and, 423, 427
 - Retinal hamartomas**, in tuberous sclerosis complex, 152, 154
 - Retinoic acid**, to pretreat face, for chemical peels, 269
 - Retinoids**, for xeroderma pigmentosum, 199
 - systemic. See *Systemic retinoids*.

Rhabdomyomas, cardiac, in tuberous sclerosis complex, 154
 fetal, in nevoid basal cell carcinoma syndrome, 120

Rheumatoid arthritis, vs. psoriatic arthritis, 788

Rheumatoid factor, in psoriatic arthritis, 788

Rhytides, dermabrasion for, 315-316

Rombo syndrome, basal cell carcinoma in, 121

Rothmund-Thomson syndrome, 143-150
 age of onset of, 144
 differential diagnosis of, 145
 etiology of, 148
 histopathology of, 144-145
 malignancies associated with, 147-148
 management of, 148-149
 mucocutaneous stigmata of, 143-145
 noncutaneous features of, 145-147
 genetics in, 145-146
 growth and development, 146-147
 ocular abnormalities, 146
 skeletal abnormalities, 146

Ruby lasers, in cosmetic dermatology, 453-454, 456

SAPHO syndrome, with psoriatic arthritis, 786

Scabies, in HIV infection, 235

Scalp, psoriasis of, 771-772

Scalp reduction, in hair transplantation. See *Hair transplantation*.

Scarabrasion, with dermabrasion, 325

Scarlet fever, and psoriasis, 719

Scarring, acne, dermabrasion for, 313-315
 hypertrophic, chemical peels and, 271, 294, 311
 dermabrasion and, 323

microlipoinjection of Fibrel for, 357-358

Schwannomas, in Carney complex. See *Carney complex*.
 vestibular, in neurofibromatosis, 109

Scleral show, blepharoplasty and, 422

Sclerotherapy, for varicose and telangiectatic veins, 431-445
 compression following, 442
 historical aspects of, 431
 patient evaluation for, 431-439
 continuous wave Doppler ultrasound in, 435-437
 duplex ultrasound in, 439
 history in, 432
 photoplethysmography in, 437, 439
 physical examination in, 432, 434-435
 solutions for, 439-442
 detergent, 440-441
 irritant or caustic, 441-442
 osmotic, 441

Sebaceous gland tumors, in Muir-Torre syndrome, 81-82

Seborrheic dermatitis, in HIV infection, 235-236

Sedation, in tumescent liposuction, 337

Seizures, in tuberous sclerosis complex, 156

Serum alphafetoprotein, in ataxia-telangiectasia, 3

Serum sickness reactions, drug-induced, 685

Shagreen patch, in tuberous sclerosis complex, 152

Sipple syndrome. See *Multiple endocrine neoplasia 2A*.

Skeletal abnormalities, in Cowden syndrome, 29
 in dyskeratosis congenita, 35
 in Rothmund-Thomson syndrome, 146

Skin cancer, 583-594
 analytic epidemiology of, 586-591
 association with cutaneous sun sensitivity, 586-587
 association with personal sun exposure, 588-589
 pattern of exposure, 589
 quantitative relationship to sun exposure, 589

burns, trauma, and ulceration and, 591

chemical exposure and, 590

descriptive epidemiology of, 583-586
 anatomic site distribution, 586
 and sun exposure, 586

incidence measurement, 583-584

incidence patterns, 584-585

mortality measurement, 584
 time trends in incidence, 585-586

diet and, 590-591

epidermolysis bullosa and, 666-667

female sex hormones and, 590

immune suppression and, 590

in Rothmund-Thomson syndrome, 147

in xeroderma pigmentosum, 188-189

increased risk of, therapy for psoriasis and, 720, 859-860

ionizing radiation and, 590

nonsolar ultraviolet radiation and, 589-590

prevention of, behavioral changes in, 613-622
 appearance interventions for, 616
 interventions for, 614-615
 in children and adolescents, 615-616
 stage-based, 617-618
 stage-based sun exposure, 618-619

need for, 613-614
 public knowledge, attitudes, and behavior in, 614
 stage model of, 616-617

public health issues in, 591-592

PUVA therapy and, 590

Skin diseases, in HIV infection. See *HIV infection*.

Skin refrigerants, in anesthesia, for dermabrasion, 320

Smoking, role of, in psoriasis, 641, 718

Sodium morrhuate, in sclerotherapy, for varicose and telangiectatic veins, 441

Soft tissue augmentation, for aging face. See *Microlipoinjection*.

Sotradecol, in sclerotherapy, for varicose and telangiectatic veins, 440-441

Spinal tumors, in neurofibromatosis, 109

Spotty pigmentation, in Carney complex. See *Carney complex*.

Squamous cell carcinoma, in Rothmund-Thomson syndrome, 147
 increased risk of, therapy for psoriasis and, 720, 859-860

interferon for, 703-704

Staphylococcus aureus infections, in HIV infection, 231

Stevens-Johnson syndrome, drug-induced, 683-684

Streptococcal infections, role of, in psoriasis, 718, 725-726, 741

Stretch back, in scalp reduction, in hair transplantation, 378-379

Scision, with dermabrasion, 325

Sulfapyridine, for pustular psoriasis, 762

Sulfasalazine, for psoriasis, 912
 for psoriatic arthritis, 790

Sunscreen intolerance, 473-481
 contact and photocontact sensitization in, 473-475, 477-478
 cross-sensitization reactions in, 475-476
 in photodermatoses, 476-477
 in United States, 477
 patch and photopatch testing in, 477-478

Sunscreens, for aging face, 248

Supernumerary nipples, malignancies associated with, 220-226

Synovitis, in psoriatic arthritis, 782

Syphilis, in HIV infection, 232

Systemic corticosteroids, for erythrodermic psoriasis, 768

Systemic corticosteroids (*Continued*)
 for psoriatic arthritis, 790
 for pustular psoriasis, 762
 prior treatment with, and pustular psoriasis, 761–762
 Systemic glucocorticosteroids, for psoriasis, 742–744
 hypothalamic-pituitary-adrenal axis in, 927
 indications for, 927–929
 minimizing complications of, 925–939
 pharmacology of, 925–927
 side effects of, 929–937
 cardiovascular, 934
 atherosclerosis, 934
 edema, 934
 hypertension, 934
 cutaneous, 936
 gastrointestinal, 933
 nausea and vomiting, 933
 peptic ulcer disease, 933
 hematologic and cellular, 935
 blood cell effects, 935
 immunosuppression, 935
 impaired fibroplasia, 935
 hypothalamic-pituitary-adrenal axis suppression, 936–937
 metabolic, 933–934
 hyperglycemia, 933–934
 hyperlipidemia, 934
 obesity, 934
 musculoskeletal, 929–932
 growth retardation, 931–932
 muscle effects, 932
 osteonecrosis, 930–931
 osteoporosis, 929–930
 nervous system, 936
 neuropsychiatric effects, 936
 pseudotumor cerebri, 936
 obstetric and gynecologic, 934–935
 amenorrhea, 934–935
 fetal effects, 935
 ophthalmologic, 932–933
 cataracts, 932
 glaucoma, 932–933
 Systemic retinoids, for erythrodermic psoriasis, 768–769
 for palmoplantar psoriasis, 775
 for psoriasis, 743, 891–896, 916, 919–920
 dosage and schedule for, 892–893
 mechanism of action of, 891–892
 monitoring and follow-up of, 895
 side effects of, 894–895
 with methotrexate, 884
 with phototherapy, 848, 870–871, 893–894, 918
 for psoriatic arthritis, 791
 for pustular psoriasis, 762
 Systemic sclerosis, interferons for, 707–708

Tachyphylaxis, topical corticosteroids and, for psoriasis, 812–813

Tars, for psoriasis, 818–822
 as monotherapy, 819–820
 in Goeckerman regimen, 820–822
 mechanisms of action of, 819
 pharmacologic variability of, 818–819
 vs. phototherapy, 821–822
 with phototherapy, 843–844

Tattoos, removal of, dermabrasion in, 316
 lasers in. See *Lasers*.

Telangiectatic veins, sclerotherapy for. See *Sclerotherapy*.

Tenosynovitis, in psoriatic arthritis, 785

Terbinafine, for dermatophytosis, in HIV infection, 235

Testicular large cell calcifying Sertoli cell tumors, in Carney complex, 24

Thalassemia, malignancies associated with, 60

6-Thioguanine, for psoriasis, 875, 886
 for pustular psoriasis, 763

Thiotepa, for psoriasis, 887

Thromboembolic disease, increased risk of, therapy for psoriasis and, 720

Thyroid cancer, in Gardner's syndrome, 54

Thyroid gland lesions, in Cowden syndrome, 28

T-lymphocytes, in psoriasis, 740–741

Topical corticosteroids, for erythrodermic psoriasis, 768 for psoriasis, 805–815, 916–917
 in maintenance treatment, 809–810
 mechanism of action of, 806–807
 of scalp, 771–772
 pharmacology of, 807–808
 physiology of, 805–806
 potent preparations of, 808–809
 side effects of, 810–813
 cutaneous, 811–813
 systemic, 811
 with phototherapy, 810, 847–848, 868–869
 for pustular psoriasis, 762
 prior treatment with, and pustular psoriasis, 761–762

Tourniquets, in physical examination, of varicose and telangiectatic veins, 434

Toxic epidermal necrolysis, drug-induced, 683–684

Transferrin saturation, measurement of, in HLA-linked hemochromatosis, 61

Transfusions, blood, and leishmaniasis, 516–517

Transplantation, hair. See *Hair transplantation*.

Tretinoin, to pretreat face, for dermabrasion, 319
 topical, for aging face, 249, 251

Trichloroacetic acid, in chemical peels. See *Chemical peels*.

Trichodiscomas, in Birt-Hogg-Dube syndrome, 215

Trichothiodystrophy, vs. xeroderma pigmentosum, 195

Tuberous sclerosis complex, 151–161
 cardiovascular complications of, 154
 cutaneous features of, 151–152
 diagnosis of, 160
 genetics of, 151
 neurologic features of, 156, 160
 ophthalmologic findings in, 152, 154
 pulmonary complications of, 156
 renal complications of, 154, 156

Tumescent liposuction, 329–338
 anesthesia for, 329–330
 complications of, 337
 diet after, 336
 healing process in, 336–337
 immediate postoperative recovery in, 330–331
 physical activity after, 336
 postoperative compression requirements in, 331
 postoperative drainage in, 333–335
 absorbent dressings for, 335–336
 technique for, 330

Tumescent Liposuction Garments in, 331–333
 application of, 332–333
 duration of, 333
 laundering of, 333
 removal of, 333
 wound care and bathing after, 336
 written aftercare instructions in, 331

Tumescent Liposuction Garments. See *Tumescent liposuction*.

Tumors, desmoid, in Gardner's syndrome, 52
 ovarian, in Peutz-Jeghers syndrome, 130

Tumors (Continued)

peripheral nerve sheath, in neurofibromatosis, 109
sebaceous gland, in Muir-Torre syndrome, 81–82
spinal, in neurofibromatosis, 109
testicular large cell calcifying Sertoli cell, in Carney complex, 24

Turcot's syndrome. See *Gardner's syndrome*.

Tylosis, hereditary, malignancies associated with, 218–219

Ulceration, role of, in skin cancer, 591

Ultrasound, in physical examination, of varicose and telangiectatic veins, 435–437, 439

Ultraviolet radiation, nonsolar, role of, in skin cancer, 589–590

Umbilical cord blood transplantation, for Fanconi anemia, 46

Ungual fibromas, in tuberous sclerosis complex, 152

Upper lips, dermabrasion of, 259–261

UVB therapy. See also *Phototherapy*.

for erythrodermic psoriasis, 769

for psoriasis, 827–828, 917

vs. tars, 821–822

with methotrexate, 883–884

with PUVA therapy, 870

Varicella-zoster virus, in HIV infection, 233

Varicose veins, sclerotherapy for. See *Sclerotherapy*.

Vascular lesions, removal of, lasers in. See *Lasers*.

Verruca vulgaris, interferons for, 706

Vestibular schwannomas, in neurofibromatosis, 109

Viral infections, chemical peels and, 310

in HIV infection. See *HIV infection*.

Vitamin A and D derivatives, for psoriasis, 728

Vitamin D₃ analogues, for psoriasis. See *Calcipotriol*.

Vitiligo, dermabrasion for, 316

Werner's syndrome, 163–168

cutaneous features of, 164

historical aspects of, 163–164

malignancies associated with, 164, 166–167

work-up for, 167

Wiskott-Aldrich syndrome, malignancies associated with, 68–69

Wound defects, closure of, island grafts in. See *Island grafts*.

Xeroderma pigmentosum, 169–209

biochemical and immunologic deficiencies in, 187

clinical features of, 187–190

complementation group A, 190–191

complementation group B, 191–192

complementation group C, 192

complementation group D, 192–193

complementation group E, 193

complementation group F, 193

complementation group G, 193–194

diagnosis of, 197–198

DNA repair genes in, 195–199

effects of ultraviolet rays in human tissues, 170

responses to, 170–187

cellular sensitivity to ultraviolet radiation, 181

complementation group analysis, 179, 181

host-cell reactivation studies, 181, 183

mutagenesis, 183

nonhuman eukaryotic nucleotide excision repair systems, 184, 186–187

other DNA repair systems, 173

repair of altered bases: FAPY protein, 170

repair of pyrimidine dimers and bulky adducts, 171–173

specificity of repair defect, 176, 179

studies in cell-free systems, 183–184

unscheduled DNA synthesis, 173–174, 176

variant complementation group, 181

information resources for, 199

management of, 198–199

variant complementation group, 194–195

X-linked lymphoproliferative disorder, malignancies associated with, 69–70

Yellow light lasers, in cosmetic dermatology, 449–451

Zidovudine, for psoriasis, in HIV infection, 236